Multicell Techs Morgan Bond
Multicell Techs' financial leverage is the degree to which the firm utilizes its fixed-income securities and uses equity to finance projects. Companies with high leverage are usually considered to be at financial risk. Multicell Techs' financial risk is the risk to Multicell Techs stockholders that is caused by an increase in debt. In other words, with a high degree of financial leverage come high-interest payments, which usually reduce Earnings Per Share (EPS).
Multicell |
Popular Name | Multicell Techs Morgan Stanley 3971 |
Equity ISIN Code | US62544S2005 |
Bond Issue ISIN Code | US61744YAL20 |
S&P Rating | Others |
Maturity Date | 22nd of July 2038 |
Issuance Date | 24th of July 2017 |
Coupon | 3.971 % |
Multicell Techs Outstanding Bond Obligations
Dana 575 percent | US235822AB96 | Details | |
Volcan Compania Minera | USP98047AC08 | Details | |
Boeing Co 2196 | US097023DG73 | Details | |
HSBC Holdings PLC | US404280DR76 | Details | |
MPLX LP 4875 | US55336VAG59 | Details | |
MPLX LP 52 | US55336VAL45 | Details | |
US62548LAA08 | US62548LAA08 | Details | |
International Game Technology | US460599AD57 | Details | |
Morgan Stanley 3591 | US61744YAK47 | Details | |
Morgan Stanley 3971 | US61744YAL20 | Details | |
MGM Resorts International | US552953CD18 | Details |
Understaning Multicell Techs Use of Financial Leverage
Multicell Techs' financial leverage ratio measures its total debt position, including all of its outstanding liabilities, and compares it to Multicell Techs' current equity. If creditors own a majority of Multicell Techs' assets, the company is considered highly leveraged. Understanding the composition and structure of Multicell Techs' outstanding bonds gives an idea of how risky it is and if it is worth investing in.
MultiCell Technologies, Inc., a biopharmaceutical company, develops novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and interventional cardiology and peripheral vessel applications. MultiCell Technologies, Inc. was founded in 1962 and is headquartered in Woonsocket, Rhode Island. Multicell Techs operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 2 people. Please read more on our technical analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Multicell Pink Sheet Analysis
When running Multicell Techs' price analysis, check to measure Multicell Techs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Multicell Techs is operating at the current time. Most of Multicell Techs' value examination focuses on studying past and present price action to predict the probability of Multicell Techs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Multicell Techs' price. Additionally, you may evaluate how the addition of Multicell Techs to your portfolios can decrease your overall portfolio volatility.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.